Abstract
Sorafenib was recently approved by both the FDA and EMA for the treatment of unresectable hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and thyroid cancer (DTC). This paper proposes a physiologically based model to describe its pharmacokinetic properties. Special attention is devoted to the enterohepatic circulation, which causes the characteristic double-peak in the drug’s concentration–time curves. This physiologically based pharmacokinetic (PBPK) model has a structure suitable for different mammals. The paper focuses on the anatomy and physiology of mice aiming to develop a physiologically consistent model to produce accurate simulation of sorafenib pharmacokinetics, in agreement with literature data. The in silico description of sorafenib pharmacokinetics allows understanding further its properties, by complementing the experimental data with numerical simulations based on a mechanistic approach. Modeling and simulation is a rapidly growing branch of quantitative systems pharmacology and...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
